Theravance Biopharma Submits IBD Drug for FDA Investigational Approval

Theravance Biopharma Submits IBD Drug for FDA Investigational Approval
Theravance Biopharma, Inc., a company focused on underserved markets related to infectious diseases, lung and gastrointestinal tract disorders, recently announced in a press release the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for its investigational product TD-1473, a potential therapy for inflammatory intestinal conditions. TD-1473 is

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *